NanoDendrixTM can increase the solubility and stability of existing antibiotics or NanoDendrixTM itself can be chemically modified to exhibit anti-infective properties. Current Glysantis R&D activities are investigating the use of native and chemically modified NanoDendrixTM in the following applications:

  • Developing a novel antimicrobial agent based on NanoDendrixTM derivatives.
  • Increasing the solubility of poorly water-soluble drugs: In the context of drug formulation,NanoDendrixTM can increase the solubility of poorly soluble antimicrobials like thymol, clarithromycin and thiostrepton which can allow for the use of higher concentration formulations of these under-utilized drugs.
  • Antibiotic potentiation: Modified NanoDendrixTM can synergize with various antibiotics and reduce their minimum inhibitory concentrations (MIC), a measure of an antibiotic’s potency. This strategy could allow for a reduction in the dose of a specific antibiotic, when complexed with NanoDendrixTM. This strategy will also target antibiotic-resistant strains of bacteria by making them more susceptible to current antibiotics on the market.
  • Anti-biofilm: Modified NanoDendrixTM can disrupt the formation of biofilms – protective layers of an extracellular matrix produced by microbes, composed of extracellular polymeric substances (EPSs) like sugars and glycoproteins, that shield bacteria from antimicrobial drugs. Biofilms form on all types of surfaces exposed to bacteria – from medical catheters to drainage pipes; even dental plaque is a type of biofilm. This is another strategy aimed at targeting drug-resistant microbes by disrupting the formation of protective biofilms.